Importantly, while our results provide exciting evidence that NKp44-PCNA blocking can potentiate NK cell-mediated anti-tumor responses, the impact of the mAb 14-25-9 on the response of NK cells to distinct cancer types requires further studies. The gene discussed is NCR2; the disease is cancer.